Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system

Anti-Cancer Drugs

Volumn 10, Issue 3, 1999, Pages 303-307

  Diab, Sami G ^a,b   Hilsenbeck, Susan G ^a   Izbicka, Elzbieta ^a   Weitman, Steven D ^a   Von Hoff, Daniel D ^a  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Diarylsulfonylurea; Human tumor cloning; Ly295501; System

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 (2,3 DIHYDROBENZOFURAN 5 YLSULFONYL)UREA; CYTOTOXIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CLONING; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZOFURANS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PHENYLUREA COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0032788211     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199903000-00009     Document Type: Article

References (26)

1. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 1993; 5: 223-8.
2. Houghton PJ, Houghton JA. Antitumor diarylsulfonylureas: novel agents with unfulfilled promise. Invest New Drugs 1996; 14: 271-80.
3. Phelps PC, Best CJ, Berezesky IK, et al. Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorgenic rat kidney cell lines. Cancer Lett 1995; 97: 7-15.
4. Hainsworth JD, Hande KR, Satterlee WG, et al. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res 1989; 49: 5217-20.
5. Krarup-Hansen A, Pedersen H, Andersen E, et al. Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours. Invest New Drugs 1997; 15: 147-51.
6. Pratt CB, Bowman LC, Marina N, et al. A phase I study of sulofenur in refractory pediatric malignant solid tumors. Invest New Drugs 1995; 13: 63-6.
7. Weinerman B, Eisenhauer E, Stewart D, et al. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer. Ann Oncol 1992; 3: 83-4.
8. Kamthan A, Scarffe JH, Walling J, et al. A phase II study of sulofenur (LY186641) in gastric cancer. Anti-Cancer Drugs 1992; 3: 331-5.
9. Brown TD, ORourke TJ, Kuhn JG, et al. Phase I trial of sulofenur (LY186641) given orally on a daily × 21 schedule. Anti-Cancer Drugs 1994; 5: 151-9.
10. Taylor CW, Alberts DS, Ketcham MA, et al. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J Clin Oncol 1989; 7: 1733-40.
11. Talbot DC, Smith IE, Nicolson MC, et al. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemother Pharmacol 993; 31: 419-22.
12. OBrien ME, Hardy J, Tan S, et al. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 1992; 30: 245-8.
13. Molthrop DC Jr, Wheeler RH, Hall KM, et al. Evaluation of the methemoglobinemia associated with sulofenur. Invest New Drugs 1994; 12: 99-102.
14. Houghton PJ, Cheshire PJ, Myers I, et al. Efficacy of sulofenur and a second generation diarylsulfonylurcea, N- [5-(2, 3-dihydrobenzofuryl) sulfonyl]-N-(3,4-dichlorophenyl) urea (LY295501), against colon adenocarcinoma xenografts. Anti-Cancer Drugs 1995; 6: 317-23.
15. LY295501 clinical investigators brochure. Lilly Research Laboratories.
16. Schultz RM, Andis SL, Toth JE, et al. Effect of albumin on antitumor activity of diarylsulfonylureas. Anticancer Res 1993; 13: 1939-43.
17. Von Hoff DD, Coltman CA, Forseth B, et al. Activity of mitoxantrone in a human tumor cloning system. Cancer Res 1981; 41: 1853-5.
18. Shoemaker RH, Wolpert-Defillipes MK, et al. Application of a human tumor colony-forming assay to a new drug screening. Cancer Res 1985; 45: 2134-53.
19. Von Hoff DD, Huong AM, Collin J. Effect of recombinant beta interferon on primary human tumor colony forming units. J Interferon Res 1988; 8: 813-20.
20. Salmon SE, Liu R. Effects of granulocyte-macrophage colony stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 1989; 7: 3146-50.
21. Foulke RS, Marshall MH, Trotta PP, Von Hoff DD. In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264-7.
22. Hanauske U, Hanauske AR, Marshall MH, et al. Biphasic effect of vanadium salts on in vitro tumor colony growth. Int J Cell Cloning 1987; 5: 170-8.
23. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 1990; 82: 110-6.
24. DeMaria D. Stevenson JP, Mitchell E, et al. Phase I trial of the diarylsulfonylurea LY295501 administered on a weekly × 3 schedule. In: Proc 10th NCI-EORTC Sympo on New Drugs in Cancer Therapy 1998: abstr 438.
25. Beale P, Judson I, Rees C, et al. Phase I trial of the diarylsufonylurea LY295501 administered orally once daily for 5 days every 28 days. In: Proc 10th NCI-EORTC Symp on New Drugs in Cancer Therapy 1998: abstr 439.
26. Diab S, Baker S D, Hammond L, et al. Phase I and pharmacokinetic (pk) study of the diarylsulfonylurea LY295501 administered as a single oral dose weekly for 3 weeks every 4 weeks. In: Proc 10th NCI-EORTC Symp on New Drugs in Cancer Therapy 1998: abstr 440.